Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia

Journal of the American Society of Nephrology

Volumn 8, Issue 12, 1997, Pages 1899-1905

  Perna, Alessandra F ^a   Ingrosso, Diego ^a   De Santo, Natale G ^a   Galletti, Patrizia ^a   Brunone, Massimiliano ^a   Zappia, Vincenzo ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; METHIONINE; METHYLTRANSFERASE; PREFOLIC; S ADENOSYLMETHIONINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; DRUG BINDING; DRUG EFFICACY; ENZYME INHIBITION; HOMOCYSTINURIA; HUMAN; HUMAN CELL; HUMAN TISSUE; METHYLATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK FACTOR; UREMIA;

EID: 0031421041     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I: Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 324: 1149-1155, 1991
2. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 268: 877-881, 1992
3. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G: Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults: The atherosclerosis risk in communities study. Circulation 87: 1107-1113, 1993
4. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland PM, Kvale G: Total plasma homocysteine and cardiovascular risk profile: The Hordaland homocysteine study. JAMA 274: 1526-1533, 1995
5. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, Kottke-Marchant K, Savon SR, Seihub J, Nissen SE, Kutner M, Topol EJ, Jacobsen DW: Hyperhomocysteinemia and low pyridoxal phosphate: Common and independent reversible risk factors for coronary artery disease. Circulation 92: 2825-2830, 1992
6. Parfrey PS: Cardiac and cerebrovascular disease in chronic uremia. Am J Kidney Dis 21: 77-80, 1993
7. Wilcken DEL, Gupta VJ, Reddy SG: Accumulation of sulfur-containing amino acids including cysteine-homocysteine in patients on maintenance haemodialysis. Clin Sci 58: 427-430, 1980
8. Chauveau P, Chadefaux B, Coudé M, Aupetit J, Hannedouche T, Kamoun P, Jungers P: Increased plasma homocysteine concentration in patients with chronic renal failure. Miner Electrolyte Metab 1992;18:196-198.
9. Chauveau P, Chadefaux B, Coudè M, Aupetit J, Hannedouche T, Kamoun P, Jungers P: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 43: S72-S77, 1993
10. Hultberg B, Andersson A, Sterner G: Plasma homocysteine in renal failure. Clin Nephrol 40: 230-235, 1993
11. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6: 121-125, 1995
12. Guttormsen AB, Svarstad E, Ueland PM, Refsum H: Elimination of homocysteine from plasma in subjects with end stage renal failure. Ir J Med Sci 164: (S)8-(S)9, 1995
13. Bostom AG, Brosnan JT, Hall B, Nadeau MR, Selhub J: Homocysteine metabolism by the rat kidney in vivo. Ir J Med Sci 164: (S)2-(S)3, 1995
14. Bostom AG, Brosnan JT, Hall B, Nadeau MR, Selhub J: Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 116: 59-62, 1995
15. Robinson K, Gupta A, Dennis V, Arheart D, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen DW: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and piridoxine concentrations. Circulation 94: 2743-2748, 1996
16. Dennis VW, Robinson K: Homocysteinemia and vascular disease in end stage renal disease. Kidney Int 50(57): S11-S17, 1996
17. Perna AF, Ingrosso D, Zappia V, Galletti P, Capasso G, De Santo NG: Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure: Evidence for high levels of the natural inhibitor S-adenosylhomocysteine. J Clin Invest 91: 2497-2503, 1993
18. Zappia V, Zydek-Cwick CR, Schlenk F: The specificity of S-adenosylmethionine derivatives in methyl transfer reactions. J Biol Chem 244: 4499-4505, 1969
19. Cantoni GL, Richards HH, Chiang PK: Inhibitors of S-adenosylhomocysteine hydrolase and their role in the regulation of biological methylation. In: Transmethylations, edited by Usdin E, Borchard RT, Creveling CR, Amsterdam, Elsevier/North Holland, 1979, pp 155-164
20. Cantoni GL, Chiang PK: The role of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase in the control of biologic methylations. In: Natural Sulfur Compounds: Novel Biochemical and Structural Aspects, edited by Cavallini D, Gaull GE, Zappia V, New York, Plenum Press, 1980, pp 67-89
21. Barber JR, Clarke S: Inhibition of protein carboxyl methylation by S-adenosyl-L-homocysteine in intact erythrocytes: Physiological consequences. J Biol Chem 259: 7115-7122, 1984
22. Cantoni GL: The centrality of S-adenosylhomocysteinase in the regulation of the biological utilization of S-adenosylmethionine. In: Biological Methylation and Drug Design: Experimental and Clinical Roles of S-adenosylmethionine, edited by Borchardt RT, Creveling CR, Ueland PM, Clifton NJ, Humana Press, 1986, pp 227-238
23. Perna AF, Ingrosso D, Galletti P, Zappia V, De Santo NG: Membrane protein damage and methylation reactions in chronic renal failure. Kidney Int 50: 358-366, 1996
24. Galletti P, Ingrosso D, Manna C, Clemente G, Zappia V: Protein damage and methylation mediated repair in the erythrocyte. Biochem J 306: 313-325, 1995
25. Perna AF, D'Aniello A, Lowenson JD, Clarke S, De Santo NG, Ingrosso D: D-aspartate content of erythrocyte membrane proteins is decreased in uremia: implications for the repair of damaged proteins. J Am Soc Nephrol 8: 95-104, 1997
26. Mudd SH, Levy HL, Skovby F: Disorders of transsulfuration. In: The Metabolic Basis of Inherited Disease, edited by Scriver CR, Beaudet AL, Sly WS, Valle D, New York, McGraw Hill, 1989, pp 693-737
27. Selhub J, Miller JW: The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 55: 131-138, 1992
28. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism 37: 697-701, 1988
29. Arnadottir M, Brattstrom LA, Simonsen O, Thysell H, Hultberg B, Andersson A, Nilsson-Ehle P: The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 40: 236-240, 1993
30. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49: 147-152, 1996
31. Macfarlane DE: Inhibitors of cyclic nucleotide phosphodiesterases inhibit protein carboxyl methylation in intact blood platelets. J Biol Chem 259: 1357-1362, 1984
32. Ubbink JB, Vermaak WJH, Bissbort S: Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 565: 441-446, 1991
33. Perna AF, Ingrosso D, De Santo NG, Galletti P, Zappia V: Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int 47: 247-253, 1995
34. Jones BN, Paabo S, Stein S: Amino acid analysis and enzymatic sequence determination of peptides by an improved o-phtalaldehyde precolumn labeling procedure. J Liq Chromatogr 4: 565-586, 1981
35. Dawson-Saunders B, Trapp RG: Basic and Clinical Biostatistics, Norwalk, CT, Appleton & Lange, 1990
36. Tsai C, Perrella MA, Yoshizumi M, Hsien C-M, Habe E, Schlagel R, Lee M-E: Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 91: 6369-6373, 1994
37. Harpel PC, Chang VT, Bort W: Homocysteine and other sulf-hydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 89: 10193-10197, 1992
38. Preibisch G, Kuffner C, Elstner EF: Biochemical model reactions on the prooxidative activity of homocysteine. J Biosci 48: 58-62, 1993
39. Rodgers GM, Kane WH: Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 77: 1909-1916, 1986
40. Hayashi T, Honda G, Suzuki K: An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 79: 2930-2936, 1992
41. Laidlaw SA, Smolin LA, Davidson WD, Kopple JD: Sulfur amino acids in maintenance hemodialysis patients. Kidney Int 32: S191-S196, 1987
42. Westhuyzen J, Matherson K, Tracey R, Fleming SJ: Effect of withdrawal of folic acid supplementation in maintenance hemodialysis patients. Clin Nephrol 40: 96-99, 1993
43. Janssen MJFM, van den Berg M, van Guldener C, Boers GHJ, Stehouwer CDA: Withdrawal of folic acid supplementation in maintenance hemodialysis patients. Clin Nephrol 42: 136-137, 1994
44. Toigo G, Situlin R, Vasile A, Guerra UP, Tamaro G, Pagoni G, Sergiani G, Russo M, Guarnieri G: Effects of erythropoietin administration on nutritional state and erythrocyte metabolism in maintenance hemodialysis patients. In: Metabolic and Nutritional Abnormalities in Kidney Disease. Contrib Nephrol 98: 79-88, 1992